Key result
AF screening in LMICs identifies ~1% confirmed AF, but anticoagulation coverage remains low.
Why the study?
What are the detection rates, reach, diagnostic confirmation, and anticoagulation uptake of population-facing atrial fibrillation screening-to-anticoagulation pathways in low- and middle-income countries?
Meta-Analysis
Yes
What are the detection rates, reach, diagnostic confirmation, and anticoagulation uptake of population-facing atrial fibrillation screening-to-anticoagulation pathways in low- and middle-income countries?
Atrial fibrillation screening in low- and middle-income countries reveals substantial, highly variable detection and treatment gaps, with only 22.8% oral anticoagulation coverage among eligible high-risk individuals.
Answers are grounded in this paper and cite their sources.
AF screening pathways in LMICs show implementation gaps; leaves open optimal strategies and equity impact pending prospective trials.
Atrial fibrillation (AF) is an important cause of preventable stroke in low- and middle-income countries (LMICs), where diagnostic and treatment gaps may limit screening effectiveness. This study aims to evaluate AF screening in LMICs as a screening-to-anticoagulation pathway, focusing on reach, equity, diagnostic confirmation, anticoagulation uptake, and health-system capacity. MEDLINE via PubMed, Embase, CINAHL, Web of Science, and CENTRAL were searched from inception to July 2026. LMIC studies reporting population-facing AF screening or screening-linked care were included. Logit-transformed proportions were pooled using restricted maximum-likelihood random-effects models with modified Hartung-Knapp CIs; binomial-normal generalized linear mixed models were used in sensitivity analyses. Pathway stages were synthesized from outcome-specific study subsets rather than a single longitudinal cohort. Thirty-seven reports from 13 LMICs and 1 multinational cohort were included. Across 22 community- or population-based studies, confirmed AF averaged 1.24% (95% CI: 0.79%-1.94%; I2 = 98.8%; 95% prediction interval: 0.16%-8.83%). Newly detected AF averaged 0.95% (95% CI: 0.43%-2.11%; I2 = 99.2%; prediction interval: 0.08%-9.97%). In separate study subsets, prior AF awareness was 50.7%, study-defined high stroke risk or oral anticoagulation indication was 78.9%, and oral anticoagulation coverage among study-defined eligible/high-risk participants was 22.8%. Reach ranged from 9.7% to 98.8%, and confirmation completion was 57.5% to 61.8% in 2 programs. AF screening in LMICs identifies substantial but highly variable detection and treatment gaps. Pooled proportions should be interpreted as cross-study summaries rather than expected rates for a specific setting. Effective programs require representative reach, timely confirmation, appropriate stroke-risk and valvular assessment, access to anticoagulation, and longitudinal follow-up.
No takes yet. Share an insight, caveat, or question.
Jamileh et al. (2026) conducted a meta-analysis in Atrial fibrillation. Population-facing atrial fibrillation screening-to-anticoagulation pathways was evaluated on Confirmed atrial fibrillation prevalence across community- or population-based screening studies (Pooled proportion 1.24%, 95% CI 0.79%-1.94%). AF screening in LMICs identified 1.24% confirmed AF and 0.95% newly detected AF, with 22.8% anticoagulation coverage among high-risk patients.
Synapse has enriched 10 related papers. Consider them for comparative context: